Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.
2.

Persistent Hotspots in Schistosomiasis Consortium for Operational Research and Evaluation Studies for Gaining and Sustaining Control of Schistosomiasis after Four Years of Mass Drug Administration of Praziquantel.

Kittur N, King CH, Campbell CH, Kinung'hi S, Mwinzi PNM, Karanja DMS, N'Goran EK, Phillips AE, Gazzinelli-Guimaraes PH, Olsen A, Magnussen P, Secor WE, Montgomery SP, Utzinger J, Walker JW, Binder S, Colley DG.

Am J Trop Med Hyg. 2019 Sep;101(3):617-627. doi: 10.4269/ajtmh.19-0193.

3.

Young Adults in Endemic Areas: An Untreated Group in Need of School-Based Preventive Chemotherapy for Schistosomiasis Control and Elimination.

Korir HK, Riner DK, Kavere E, Omondi A, Landry J, Kittur N, Ndombi EM, Ondigo BN, Secor WE, Karanja DMS, Colley DG.

Trop Med Infect Dis. 2018 Sep 5;3(3). pii: E100. doi: 10.3390/tropicalmed3030100.

4.

Relative Contribution of Schistosomiasis and Malaria to Anemia in Western Kenya.

Valice EM, Wiegand RE, Mwinzi PNM, Karanja DMS, Williamson JM, Ochola E, Samuels A, Verani JR, Leon JS, Secor WE, Montgomery SP.

Am J Trop Med Hyg. 2018 Sep;99(3):713-715. doi: 10.4269/ajtmh.18-0069. Epub 2018 Jul 5.

5.

Impact of Mothers' Schistosomiasis Status During Gestation on Children's IgG Antibody Responses to Routine Vaccines 2 Years Later and Anti-Schistosome and Anti-Malarial Responses by Neonates in Western Kenya.

Ondigo BN, Muok EMO, Oguso JK, Njenga SM, Kanyi HM, Ndombi EM, Priest JW, Kittur N, Secor WE, Karanja DMS, Colley DG.

Front Immunol. 2018 Jun 18;9:1402. doi: 10.3389/fimmu.2018.01402. eCollection 2018.

6.

Functional Studies of T Regulatory Lymphocytes in Human Schistosomiasis in Western Kenya.

Ondigo BN, Ndombi EM, Nicholson SC, Oguso JK, Carter JM, Kittur N, Secor WE, Karanja DMS, Colley DG.

Am J Trop Med Hyg. 2018 Jun;98(6):1770-1781. doi: 10.4269/ajtmh.17-0966. Epub 2018 Apr 19.

7.

Effect of four rounds of annual school-wide mass praziquantel treatment for schistosoma mansoni control on schistosome-specific immune responses.

Ndombi EM, Abudho B, Kittur N, Carter JM, Korir H, Riner DK, Ochanda H, Lee YM, Secor WE, Karanja DM, Colley DG.

Parasite Immunol. 2018 Jun;40(6):e12530. doi: 10.1111/pim.12530. Epub 2018 Apr 29.

8.

Impact of Four Years of Annual Mass Drug Administration on Prevalence and Intensity of Schistosomiasis among Primary and High School Children in Western Kenya: A Repeated Cross-Sectional Study.

Abudho BO, Ndombi EM, Guya B, Carter JM, Riner DK, Kittur N, Karanja DMS, Secor WE, Colley DG.

Am J Trop Med Hyg. 2018 May;98(5):1397-1402. doi: 10.4269/ajtmh.17-0908. Epub 2018 Mar 8.

9.

Cluster randomized trial comparing school-based mass drug administration schedules in areas of western Kenya with moderate initial prevalence of Schistosoma mansoni infections.

Karanja DMS, Awino EK, Wiegand RE, Okoth E, Abudho BO, Mwinzi PNM, Montgomery SP, Secor WE.

PLoS Negl Trop Dis. 2017 Oct 23;11(10):e0006033. doi: 10.1371/journal.pntd.0006033. eCollection 2017 Oct.

10.

A Persistent Hotspot of Schistosoma mansoni Infection in a Five-Year Randomized Trial of Praziquantel Preventative Chemotherapy Strategies.

Wiegand RE, Mwinzi PNM, Montgomery SP, Chan YL, Andiego K, Omedo M, Muchiri G, Ogutu MO, Rawago F, Odiere MR, Karanja DMS, Secor WE.

J Infect Dis. 2017 Dec 12;216(11):1425-1433. doi: 10.1093/infdis/jix496. Erratum in: J Infect Dis. 2018 May 15;217(10):1672.

11.

Gaining and sustaining schistosomiasis control: study protocol and baseline data prior to different treatment strategies in five African countries.

Ezeamama AE, He CL, Shen Y, Yin XP, Binder SC, Campbell CH Jr, Rathbun S, Whalen CC, N'Goran EK, Utzinger J, Olsen A, Magnussen P, Kinung'hi S, Fenwick A, Phillips A, Ferro J, Karanja DM, Mwinzi PN, Montgomery S, Secor WE, Hamidou A, Garba A, King CH, Colley DG.

BMC Infect Dis. 2016 May 26;16:229. doi: 10.1186/s12879-016-1575-2.

12.

Impact of two rounds of praziquantel mass drug administration on Schistosoma mansoni infection prevalence and intensity: a comparison between community wide treatment and school based treatment in western Kenya.

Onkanga IO, Mwinzi PN, Muchiri G, Andiego K, Omedo M, Karanja DM, Wiegand RE, Secor WE, Montgomery SP.

Int J Parasitol. 2016 Jun;46(7):439-45. doi: 10.1016/j.ijpara.2016.01.006. Epub 2016 Mar 2.

13.

Predictive Value of School-Aged Children's Schistosomiasis Prevalence and Egg Intensity for Other Age Groups in Western Kenya.

Mwinzi PN, Muchiri G, Wiegand RE, Omedo M, Abudho B, Karanja DM, Montgomery SP, Secor WE.

Am J Trop Med Hyg. 2015 Dec;93(6):1311-7. doi: 10.4269/ajtmh.15-0467. Epub 2015 Sep 28.

14.

Using Photovoice as a Community Based Participatory Research Tool for Changing Water, Sanitation, and Hygiene Behaviours in Usoma, Kenya.

Bisung E, Elliott SJ, Abudho B, Karanja DM, Schuster-Wallace CJ.

Biomed Res Int. 2015;2015:903025. doi: 10.1155/2015/903025. Epub 2015 Aug 25.

15.

Is PCR the Next Reference Standard for the Diagnosis of Schistosoma in Stool? A Comparison with Microscopy in Senegal and Kenya.

Meurs L, Brienen E, Mbow M, Ochola EA, Mboup S, Karanja DM, Secor WE, Polman K, van Lieshout L.

PLoS Negl Trop Dis. 2015 Jul 28;9(7):e0003959. doi: 10.1371/journal.pntd.0003959. eCollection 2015.

16.

Improved sensitivity of the urine CAA lateral-flow assay for diagnosing active Schistosoma infections by using larger sample volumes.

Corstjens PL, Nyakundi RK, de Dood CJ, Kariuki TM, Ochola EA, Karanja DM, Mwinzi PN, van Dam GJ.

Parasit Vectors. 2015 Apr 22;8:241. doi: 10.1186/s13071-015-0857-7.

17.

Cost analysis of tests for the detection of Schistosoma mansoni infection in children in western Kenya.

Worrell CM, Bartoces M, Karanja DM, Ochola EA, Matete DO, Mwinzi PN, Montgomery SP, Secor WE.

Am J Trop Med Hyg. 2015 Jun;92(6):1233-9. doi: 10.4269/ajtmh.14-0644. Epub 2015 Apr 13.

18.

Evaluation of point-of-contact circulating cathodic antigen assays for the detection of Schistosoma mansoni infection in low-, moderate-, and high-prevalence schools in western Kenya.

Foo KT, Blackstock AJ, Ochola EA, Matete DO, Mwinzi PN, Montgomery SP, Karanja DM, Secor WE.

Am J Trop Med Hyg. 2015 Jun;92(6):1227-32. doi: 10.4269/ajtmh.14-0643. Epub 2015 Apr 13.

19.

Dreaming of toilets: using photovoice to explore knowledge, attitudes and practices around water-health linkages in rural Kenya.

Bisung E, Elliott SJ, Abudho B, Schuster-Wallace CJ, Karanja DM.

Health Place. 2015 Jan;31:208-15. doi: 10.1016/j.healthplace.2014.12.007. Epub 2015 Jan 7.

PMID:
25576836
20.

Social capital, collective action and access to water in rural Kenya.

Bisung E, Elliott SJ, Schuster-Wallace CJ, Karanja DM, Bernard A.

Soc Sci Med. 2014 Oct;119:147-54. doi: 10.1016/j.socscimed.2014.07.060. Epub 2014 Jul 30.

PMID:
25181474
21.

Assessment of quality of life as a tool for measuring morbidity due to Schistosoma mansoni infection and the impact of treatment.

Won KY, Abudho B, Blackstock AJ, Montgomery SP, Kennedy ED, Person B, Mwinzi PN, Ochola EA, Foo KT, Hightower AW, Karanja DM, Secor WE.

Am J Trop Med Hyg. 2014 Feb;90(2):322-8. doi: 10.4269/ajtmh.13-0361. Epub 2013 Dec 9.

22.

Use of geospatial modeling to predict Schistosoma mansoni prevalence in Nyanza Province, Kenya.

Woodhall DM, Wiegand RE, Wellman M, Matey E, Abudho B, Karanja DM, Mwinzi PM, Montgomery SP, Secor WE.

PLoS One. 2013 Aug 14;8(8):e71635. doi: 10.1371/journal.pone.0071635. eCollection 2013.

23.

Association between CD4+ T-lymphocyte counts and fecal excretion of Schistosoma mansoni eggs in patients coinfected with S. mansoni and human immunodeficiency virus before and after initiation of antiretroviral therapy.

Muok EM, Simiyu EW, Ochola EA, Ng'ang'a ZW, Secor WE, Karanja DM, Mwinzi PN.

Am J Trop Med Hyg. 2013 Jul;89(1):42-5. doi: 10.4269/ajtmh.13-0045. Epub 2013 May 13.

24.

A five-country evaluation of a point-of-care circulating cathodic antigen urine assay for the prevalence of Schistosoma mansoni.

Colley DG, Binder S, Campbell C, King CH, Tchuem Tchuenté LA, N'Goran EK, Erko B, Karanja DMS, Kabatereine NB, van Lieshout L, Rathbun S.

Am J Trop Med Hyg. 2013 Mar;88(3):426-432. doi: 10.4269/ajtmh.12-0639. Epub 2013 Jan 21.

25.

High prevalence of schistosomiasis in Mbita and its adjacent islands of Lake Victoria, western Kenya.

Odiere MR, Rawago FO, Ombok M, Secor WE, Karanja DM, Mwinzi PN, Lammie PJ, Won K.

Parasit Vectors. 2012 Dec 3;5:278. doi: 10.1186/1756-3305-5-278.

26.

Faecal contamination of public water sources in informal settlements of Kisumu City, western Kenya.

Opisa S, Odiere MR, Jura WG, Karanja DM, Mwinzi PN.

Water Sci Technol. 2012;66(12):2674-81. doi: 10.2166/wst.2012.503.

PMID:
23109585
27.

Community health workers' experiences and perspectives on mass drug administration for schistosomiasis control in western Kenya: the SCORE Project.

Omedo MO, Matey EJ, Awiti A, Ogutu M, Alaii J, Karanja DM, Montgomery SP, Secor WE, Mwinzi PN.

Am J Trop Med Hyg. 2012 Dec;87(6):1065-72. doi: 10.4269/ajtmh.2012.12-0435. Epub 2012 Oct 22.

28.

Mechanism of anemia in Schistosoma mansoni-infected school children in Western Kenya.

Butler SE, Muok EM, Montgomery SP, Odhiambo K, Mwinzi PM, Secor WE, Karanja DM.

Am J Trop Med Hyg. 2012 Nov;87(5):862-7. doi: 10.4269/ajtmh.2012.12-0248. Epub 2012 Sep 17.

29.

Schistosoma mansoni morbidity among school-aged children: a SCORE project in Kenya.

Samuels AM, Matey E, Mwinzi PN, Wiegand RE, Muchiri G, Ireri E, Hyde M, Montgomery SP, Karanja DM, Secor WE.

Am J Trop Med Hyg. 2012 Nov;87(5):874-82. doi: 10.4269/ajtmh.2012.12-0397. Epub 2012 Sep 17.

30.

Integrated community-directed intervention for schistosomiasis and soil transmitted helminths in western Kenya - a pilot study.

Mwinzi PN, Montgomery SP, Owaga CO, Mwanje M, Muok EM, Ayisi JG, Laserson KF, Muchiri EM, Secor WE, Karanja DM.

Parasit Vectors. 2012 Aug 31;5:182.

31.

Malacological survey and geographical distribution of vector snails for schistosomiasis within informal settlements of Kisumu City, western Kenya.

Opisa S, Odiere MR, Jura WG, Karanja DM, Mwinzi PN.

Parasit Vectors. 2011 Dec 7;4:226. doi: 10.1186/1756-3305-4-226.

32.

You cannot prevent a disease; you only treat diseases when they occur: knowledge, attitudes and practices to water-health in a rural Kenyan community.

Levison MM, Elliott SJ, Karanja DM, Schuster-Wallace CJ, Harrington DW.

East Afr J Public Health. 2011 Jun;8(2):103-11.

PMID:
22066295
33.

Geographical distribution of schistosomiasis and soil-transmitted helminths among school children in informal settlements in Kisumu City, Western Kenya.

Odiere MR, Opisa S, Odhiambo G, Jura WG, Ayisi JM, Karanja DM, Mwinzi PN.

Parasitology. 2011 Oct;138(12):1569-77. doi: 10.1017/S003118201100059X. Epub 2011 Jun 17.

PMID:
21679486
34.

Schistosomiasis among young children in Usoma, Kenya.

Verani JR, Abudho B, Montgomery SP, Mwinzi PN, Shane HL, Butler SE, Karanja DM, Secor WE.

Am J Trop Med Hyg. 2011 May;84(5):787-91. doi: 10.4269/ajtmh.2011.10-0685.

35.

Identification of cytokeratin 18 as a biomarker of mouse and human hepatosplenic schistosomiasis.

Manivannan B, Rawson P, Jordan TW, Karanja DM, Mwinzi PN, Secor WE, La Flamme AC.

Infect Immun. 2011 May;79(5):2051-8. doi: 10.1128/IAI.01214-10. Epub 2011 Feb 28.

36.

Evaluation of urine CCA assays for detection of Schistosoma mansoni infection in Western Kenya.

Shane HL, Verani JR, Abudho B, Montgomery SP, Blackstock AJ, Mwinzi PN, Butler SE, Karanja DM, Secor WE.

PLoS Negl Trop Dis. 2011 Jan 25;5(1):e951. doi: 10.1371/journal.pntd.0000951.

37.

Increases in levels of schistosome-specific immunoglobulin E and CD23(+) B cells in a cohort of Kenyan children undergoing repeated treatment and reinfection with Schistosoma mansoni.

Black CL, Muok EM, Mwinzi PN, Carter JM, Karanja DM, Secor WE, Colley DG.

J Infect Dis. 2010 Aug 15;202(3):399-405. doi: 10.1086/653828.

38.

Influence of exposure history on the immunology and development of resistance to human Schistosomiasis mansoni.

Black CL, Mwinzi PN, Muok EM, Abudho B, Fitzsimmons CM, Dunne DW, Karanja DM, Secor WE, Colley DG.

PLoS Negl Trop Dis. 2010 Mar 23;4(3):e637. doi: 10.1371/journal.pntd.0000637.

39.

Reduced susceptibility to praziquantel among naturally occurring Kenyan isolates of Schistosoma mansoni.

Melman SD, Steinauer ML, Cunningham C, Kubatko LS, Mwangi IN, Wynn NB, Mutuku MW, Karanja DM, Colley DG, Black CL, Secor WE, Mkoji GM, Loker ES.

PLoS Negl Trop Dis. 2009 Aug 18;3(8):e504. doi: 10.1371/journal.pntd.0000504.

40.

Short report: Childhood coinfections with Plasmodium falciparum and Schistosoma mansoni result in lower percentages of activated T cells and T regulatory memory cells than schistosomiasis only.

Muok EM, Mwinzi PN, Black CL, Carter JM, Ng'ang'a ZW, Gicheru MM, Secor WE, Karanja DM, Colley DG.

Am J Trop Med Hyg. 2009 Mar;80(3):475-8. Erratum in: Am J Trop Med Hyg. 2009 Aug;81(2):370. Am J Trop Med Hyg. 2009 May;80(5):877. Mouk, Erick M O [corrected to Muok, Erick M O].

41.

Impact of intense, longitudinal retreatment with praziquantel on cure rates of schistosomiasis mansoni in a cohort of occupationally exposed adults in western Kenya.

Black CL, Steinauer ML, Mwinzi PN, Evan Secor W, Karanja DM, Colley DG.

Trop Med Int Health. 2009 Apr;14(4):450-7. doi: 10.1111/j.1365-3156.2009.02234.x. Epub 2009 Feb 14.

42.

Association of the gene polymorphisms IFN-gamma +874, IL-13 -1055 and IL-4 -590 with patterns of reinfection with Schistosoma mansoni.

Gatlin MR, Black CL, Mwinzi PN, Secor WE, Karanja DM, Colley DG.

PLoS Negl Trop Dis. 2009;3(2):e375. doi: 10.1371/journal.pntd.0000375. Epub 2009 Feb 3.

43.
44.

The life history and in vivo culture of Coelomomyces utahensis (Blastocladiomycetes).

Whisler HC, Karanja DM, Shemanchuk JA, Zebold SL, Romney SV, Nielsen LT.

J Invertebr Pathol. 2009 Jan;100(1):40-3. doi: 10.1016/j.jip.2008.09.009. Epub 2008 Sep 27.

PMID:
18854194
45.

T regulatory cell levels decrease in people infected with Schistosoma mansoni on effective treatment.

Watanabe K, Mwinzi PN, Black CL, Muok EM, Karanja DM, Secor WE, Colley DG.

Am J Trop Med Hyg. 2007 Oct;77(4):676-82.

46.

Higher percentages of circulating mast cell precursors correlate with susceptibility to reinfection with Schistosoma mansoni.

Ganley-Leal LM, Mwinzi PN, Cetre-Sossah CB, Andove J, Hightower AW, Karanja DM, Colley DG, Secor WE.

Am J Trop Med Hyg. 2006 Dec;75(6):1053-7.

PMID:
17172364
47.

Correlation between eosinophils and protection against reinfection with Schistosoma mansoni and the effect of human immunodeficiency virus type 1 coinfection in humans.

Ganley-Leal LM, Mwinzi PN, Cetre-Sossah CB, Andove J, Hightower AW, Karanja DM, Colley DG, Secor WE.

Infect Immun. 2006 Apr;74(4):2169-76.

48.

Origin and diversification of the human parasite Schistosoma mansoni.

Morgan JA, Dejong RJ, Adeoye GO, Ansa ED, Barbosa CS, Brémond P, Cesari IM, Charbonnel N, Corrêa LR, Coulibaly G, D'Andrea PS, De Souza CP, Doenhoff MJ, File S, Idris MA, Incani RN, Jarne P, Karanja DM, Kazibwe F, Kpikpi J, Lwambo NJ, Mabaye A, Magalhães LA, Makundi A, Moné H, Mouahid G, Muchemi GM, Mungai BN, Séne M, Southgate V, Tchuenté LA, Théron A, Yousif F, Zanotti-Magalhães EM, Mkoji GM, Loker ES.

Mol Ecol. 2005 Oct;14(12):3889-902.

PMID:
16202103
49.

Short report: Evaluation of hepatic fibrosis in persons co-infected with Schistosoma mansoni and human immunodeficiency virus 1.

Mwinzi PN, Karanja DM, Kareko I, Magak PW, Orago AS, Colley DG, Secor WE.

Am J Trop Med Hyg. 2004 Dec;71(6):783-6.

PMID:
15642972
50.

Interactions between schistosomiasis and human immunodeficiency virus in Western Kenya.

Secor WE, Karanja DM, Colley DG.

Mem Inst Oswaldo Cruz. 2004;99(5 Suppl 1):93-5. Epub 2004 Oct 13.

Supplemental Content

Loading ...
Support Center